Tetrahydrozoline hydrochloride
SIGMA/T4264 - ≥98% (HPLC)
Synonym: 4,5-
CAS Number: 522-48-5
Empirical Formula (Hill Notation): C13H16N2 · HCl
Molecular Weight: 236.74
EC Number: 208-329-3
MDL Number: MFCD00058029
Linear Formula: C13H16N2 · HCl
Product Type: Chemical
| assay | ≥98% (HPLC) |
| InChI | 1S/C13H16N2.ClH/c1-2-6-11 |
| InChI key | BJORNXNYWNIWEY-UHFFFAOYSA |
| originator | Novartis |
| Quality Level | 200 ![]() |
| SMILES string | Cl.C1CC(C2=NCCN2)c3ccccc3 |
| solubility | alcohol: freely soluble |
| chloroform: very slightly soluble | |
| diethyl ether: insoluble | |
| H2O: freely soluble |
| Biochem/physiol Actions: | Tetrahydrozoline is an α-adrenergic agonist and an imidazoline derivative. It plays a crucial role in the constriction of conjunctival blood vessels. Tetrahydrozoline is a common component of nasal and eye drop formulations. |
| Features and Benefits: | This compound was developed by Novartis . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 1, 10 g in poly bottle |
| Symbol | GHS07 |
| Signal word | Warning |
| Hazard statements | H302 - H315 - H319 - H335 |
| Precautionary statements | P301 + P312 + P330 - P302 + P352 - P305 + P351 + P338 |
| Hazard Codes | Xn |
| Risk Statements | 22-36/37/38 |
| Safety Statements | 26-36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| UNSPSC | 12352200 |


